ReviewCurrent hematologic malignancy reports2017
An Evidence-Based Approach to Myeloma Bone Disease.
Review in Current hematologic malignancy reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.Journal of neuro-oncology · 2025Article
- Review
- Treatment approaches for multiple Myeloma vertebral column lesions - Results from an international survey distributed to the AO spine knowledge forum tumor.Brain & spine · 2025Article
- The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma.Cancers · 2022Article
- Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma.Frontiers in oncology · 2021Review
- How Can Imaging Help the Radiation Oncologist in Multiple Myeloma Treatment.Medicina (Kaunas, Lithuania) · 2020Review
- Evidence-based supportive care in multiple myeloma.Journal of community hospital internal medicine perspectives · 2020Review
- Expression and pathogenesis of VCAM-1 and VLA-4 cytokines in multiple myeloma.Saudi journal of biological sciences · 2020Article
- Rapid study assessment in follow-up whole-body computed tomography in patients with multiple myeloma using a dedicated bone subtraction software.European radiology · 2020Article
- Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.Haematologica · 2020Article
- First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism.Annals of laboratory medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.